Health Care & Life Sciences » Pharmaceuticals | Summit Therapeutics PLC

Summit Therapeutics PLC

Summit Therapeutics PLC
Stock Exchange London Stock Exchange
EPS
GBP0.15
Market Cap
GBP38.12 M
Shares Outstanding
82.13 M
Public Float
76.37 M
Summit Therapeutics PLC ADR
Stock Exchange NASDAQ Stock Market
EPS
$1
Market Cap
$41.41 M
Shares Outstanding
32.1 M
Public Float
-

Profile

Address
136a Eastern Avenue
Abingdon Oxfordshire OX14 4SB
United Kingdom
Employees -
Website http://summitplc.com
Updated 07/08/2019
Summit Therapeutics Plc is a holding company, which engages in the discovery, development, and commercialization of novel medicines. It focuses on the genetic disease duchenne muscular dystrophy, and the infectious disease clostridium difficile infection. The company was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, United Kingdom.

Financials

View All

Glyn O. Edwards
Chief Executive Officer & Executive Director
Frank Murdoch Armstrong
Non-Executive Chairman